



HEALTH INFORMATION FOR HEALTH CARE PROVIDERS

For more information, contact:

Meredith Mackey, Public Health Nurse, Phone: (517) 264-5243, Fax: (517)264-0790, meredith.mackey@lenawee.mi.us

February 15, 2022

**IMPORTANT INFORMATION ON COVID-19 THERAPIES INCLUDING ORAL ANTIVIRAL
MEDICATION**

In December 2021, two new oral antiviral therapies, Paxlovid and molnupiravir were authorized for use under EUAs for treatment of mild to moderate COVID-19. Recently, remdesivir, an intravenous antiviral used successfully for treatment of hospitalized COVID-19 patients, was recommended by the NIH treatment panel for outpatient treatment of patients with mild to moderate COVID-19. Finally, Evusheld, a long-acting mAb was authorized for the prevention of COVID-19 (pre-exposure prophylaxis) in patients who are moderate to severely immunocompromised or have had a severe reaction to COVID vaccine. While not a substitution for vaccination, these medications represent important new approaches to reducing hospitalizations and preventing deaths in high-risk patients who qualify.

Prescribers must adhere to the requirements specified in the applicable FDA Fact Sheet for Healthcare Providers and by the state eligibility guidelines. The interim criteria, prescribing requirements and pharmacy locations with the medications will remain in effect until supply is able to meet demand and will be periodically reviewed as appropriate.

Please visit https://www.michigan.gov/coronavirus/0,9753,7-406-98178_106077---,00.html for more information.

Availability of Antiviral Medication

Paxlovid

Paxlovid may serve as an alternative to monoclonal antibody therapy in certain eligible patients when started within 5 days of symptom onset.

Paxlovid is being stocked in 47 Meijer Pharmacies in Michigan, and in selected non-Meijer retail pharmacies. Paxlovid dispensing pharmacies and current medication availability can be found at the following website: <https://rx.meijer.com/covid19/therapeuticprogram>.

Molnupiravir

Molnupiravir should only be prescribed when Paxlovid and other authorized therapies are unavailable or if a patient is ineligible to receive them.


Molnupiravir is being stocked at all Meijer Pharmacies and in selected non-Meijer pharmacies in the State of Michigan. Molnupiravir dispensing pharmacies and current medication availability can be found at the following website: <https://rx.meijer.com/covid19/therapeuticprogram>.

Questions regarding this information should be directed to: mdhhs-covid-therapies@michigan.gov.

Additional information on these medications can also be obtained at www.michigan.gov/covidtherapy

Outpatient therapy now available for those with COVID-19. Supplies may be limited.

Eligibility guidelines ensure those with the highest risks have priority access to treatments.

| Those at highest risk | Treatment window after symptoms appear: | Paxlovid PO | Sotrovimab IV | Remdesivir IV | Molnupiravir PO |
|---|---|------------------------|------------------------|------------------------|---|
| | | 5 days | 10 days | 7 days | 5 days |
|  <ul style="list-style-type: none"> 75+ years old and not up to date* Moderately or severely immunocompromised regardless of vaccine status | | ✓ | ✓ | ✓ | ✓ <i>If other therapies not available or appropriate</i> |
| | | ✓ | ✓ | ✓ | ✓ <i>If other therapies not available or appropriate</i> |
| | | ✓ | ✓ | ✓ | ✓ <i>If other therapies not available or appropriate</i> |
| | | ✓ | Not currently eligible | Not currently eligible | ✓ <i>If other therapies not available or appropriate</i> |
| | | Not currently eligible | Not currently eligible | Not currently eligible | ✓ |
| | | Not currently eligible | Not currently eligible | Not currently eligible | ✓ |
| | | Not currently eligible | Not currently eligible | Not currently eligible | ✓ |

*Up to date means a person has received all recommended COVID-19 vaccines, including booster dose(s) when eligible (bit.ly/CDCStayUpToDate).

**MI priority risk factors include:

Obesity (Body Mass Index >35), chronic respiratory disease, pregnancy (note: in pregnancy, molnupiravir should not be used and Paxlovid and remdesivir should be used with caution when sotrovimab is unavailable), chronic kidney disease (special considerations with Paxlovid), cardiovascular disease, and diabetes.

Talk to your health care provider or visit Michigan.gov/COVIDtherapy to learn more.

